# MEDYSAPIENS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medysapiens

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.medysapiens.com
- Total disclosed funding: $5.7M
- Latest round: Series A (Mar 9, 2022)
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded in 2016, MedySapiens combines technologies like bioinformatics, and artificial intelligence (AI) to develop a solution for the early diagnosis of rare genetic diseases in newborns. In March 2022, MEDYSAPIENS raised KRW 7 billion in a Series A funding from Korea Venture Investment Corporation, L&S Venture Capital, Vision Creator, and an unspecified investor. As of March 2022, Sanggoo Kang is the CEO of the company.

The product line of MedySapiens includes A.I.ssist Medy4skin, NEOseq Action panel, and A.I.ssist MedyCVi. A.I.ssist Medy4skin is an artificial intelligence system with deep learning technology that helps in evaluating the skin on 4 items like oil/moisture, wrinkles, pores, and tones. NEOseq Action panel provides therapeutics and diagnosis guidance on targeted genetic testing on diseases from actionable genes. A.I.ssist MedyCVi is a cloud solution that provides NEOseq_Action panel for neonatal intensive care unit (NICU), allowing healthcare professionals to get better accuracy.

## Funding rounds

- Series A, Mar 9, 2022, $5.7M — L&S Venture Capital, Vision Creator, Korea Venture Investment Corporation

## Investors

- L&S Venture Capital (https://capitalatlas.ai/funds/l-s-venture-capital) — Series A
- Vision Creator — Series A
- Korea Venture Investment Corporation (https://capitalatlas.ai/funds/korea-venture-investment-corporation) — Series A